Current Opinion in Infectious Diseases was launched in 1988. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of infectious diseases is divided into 11 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Monica A. Slavin
Monica A. Slavin MBBS, FRACP, MD, is based in Melbourne, Australia, where she has been Head of the Department of Infectious Diseases at the Peter MacCallum Cancer Centre since 2000 and Head of the Immunocompromised Host Infection Service at Royal Melbourne Hospital, Australia, since 2013. She is a Professor in the Department of Medicine at the University of Melbourne, Australia.
Professor Slavin received her medical degree from the University of Melbourne and trained in infectious diseases in Melbourne and in the Program in Infectious Diseases at the Fred Hutchison Cancer Research Center in Seattle, USA. She has been an infectious diseases physician since 1993 with a major interest in infections in immunocompromised patients, especially those with cancer and undergoing stem cell transplantation. Her current research focus is prevention diagnosis and early treatment of invasive fungal infections in hematology patients. She has served on national steering committees for the development of antifungal and fever and neutropenia treatment guidelines and for the conduct of Australia-wide studies of the epidemiology of fungal infection.
She is currently chair of the Australian & New Zealand Mycoses Interest Group and leads the writing group for Australasian Society for Infectious Diseases (ASID) guidelines for the use of antifungal agents in the hematology and oncology setting. She is Vice-President of the International Immunocompromised Host Society.
Professor Irving has been Professor and Honorary Consultant in Virology at the University of Nottingham, UK, and Nottingham University Hospitals NHS Trust, UK, since 2002, having previously been Senior Lecturer (1990–1996) and Reader (1997–2001).
His particular interest is in the field of viral hepatitis and he has been a member of the Department of Health Advisory Group on Hepatitis (AGH) since 1998, becoming Chair in 2009.
Professor Irving is co-chair for HCV Research UK, a multicenter, multidisciplinary effort to create a national cohort of 10,000 patients with HCV infection, together with a clinical database and biobank, to act as a resource for future research.